Aurisco(SH:605116) Zheng Quan Zhi Xing·2025-07-01 16:21Core Viewpoint - The company, Aorite Pharmaceutical Co., Ltd., is utilizing part of its idle raised funds for cash management to enhance fund efficiency and generate returns while ensuring that it does not affect the construction of fundraising projects and the use of raised funds [1][3][8] Summary by Sections Cash Management Overview - Cash management trustee: Industrial Bank Co., Ltd. Taizhou Linhai Branch [1] - Investment type: Structured deposits [1] - Cash management amount: 40 million yuan [1] - Cash management duration: 30 days [1] - The company has approved the use of idle raised funds up to 300 million yuan for cash management, valid for 12 months from the board meeting date [1][6] Cash Management Redemption Situation - The product duration was 55 days, with an investment of 40 million yuan starting from May 6, 2025, and maturing on June 30, 2025 [2] - The company redeemed the principal of 40 million yuan and received a return of 123,561.64 yuan, which met expectations [2] Purpose of Cash Management - The purpose is to improve the efficiency of raised funds, reduce financial costs, and increase returns for the company and its shareholders [3][8] Source of Funds - The company issued convertible bonds totaling 812.12 million yuan, with a net amount of 800.47 million yuan after deducting issuance costs [3] Investment Product Details - The structured deposit was purchased from Industrial Bank, with a principal amount of 40 million yuan [5] - Expected annualized return rates are 1.00% or 1.90% [5] Impact on the Company - The cash management will not affect the company's fundraising project construction and main business operations, allowing for better fund utilization and investment returns [7][8]